
Q3 Business review

January–September 2026

President and CEO Hannu Martola | 29 October 2026





Q3 2026

27.0	9.2	2.5	9.2
net sales, €m (24.7)	net sales change-% (-8.8)	EBITA excluding NRI, €m (2.8)	EBITA-% excluding NRI (11.4)

Q3: Total net sales grew by 9%

Driven by strong growth in medical and industrial

Industrial sales +32%

- Strong rebound in line-scan sales, particularly in APAC and the Americas; market share regained
- Industrial TFT sales grew 60% YoY

Medical sales +33%

- Driven by solid global CT demand
- TFT sales developed favorably, 20% of total TFT sales


Turnaround in operating cash flow, yielding to 2.9M€

Security sales -27%

- EMEIA sales hit by relocation of customer's production to APAC
- APAC sales declined due to lower cargo and CT detector demand, although the production transfer partly offset the decline
- Sales in the Americas rose strongly




Net sales by quarter




9.2

(YOY change-%)

Operating margin (EBITA) excluding NRI




Q3 2026 sales split by regional business units




	NET SALES €m	YOY CHANGE-%
AMERICAS	1.7	168.8
APAC	20.7	24.7
EMEIA	4.6	-38.9

Q3 2026 sales split by main applications




	NET SALES €m	YOY CHANGE-%
INDUSTRIAL	5.9	31.5
MEDICAL	13.9	33.4
SECURITY	7.2	-26.5



Q1-Q3 2026


77.9	9.2	6.6	8.5
net sales, €m (71.3)	net sales change-% (-6.0)	EBITA excluding NRI, €m (5.9)	EBITA-% excluding NRI (8.3)

Q1-Q3 2026 sales split by regional business units



	NET SALES €m	YOY CHANGE-%
AMERICAS	4.6	53.2
APAC	56.8	11.9
EMEIA	16.5	-6.2

Q1-Q3 2026 sales split by main applications



	NET SALES €m	YOY CHANGE-%
INDUSTRIAL	15.7	14.0
MEDICAL	39.2	23.4
SECURITY	22.9	-11.1

Key figures

	Q3 2026	Q3 2025	Q1-Q3 2026	Q1-Q3 2025	FY 2025
Net sales, EUR 1,000	26,997	24,717	77,867	71,338	101,023
Change in net sales, %	9.2%	-8.8%	9.2%	-6.0%	-6.0%
EBITA excluding NRI	2,477	2,807	6,647	5,908	9,597
EBITA excluding NRI, %	9.2%	11.4%	8.5%	8.3%	9.5%
Non-recurring items (NRI)	0	-342	0	-342	-342
EBITA, EUR 1,000	2,477	2,465	6,647	5,566	9,255
EBITA, %	9.2%	10.0%	8.5%	7.8%	9.2%
R&D costs, EUR 1,000	2,903	2,723	8,499	8,504	11,266
R&D costs, % of net sales	10.8%	11.0%	10.9%	11.9%	11.2%
Cash flow from operating activities, EUR 1,000	2,940	492	-1,099	2,389	3,885
Investments, EUR 1,000	806	504	4,484	2,052	2,965
Return on net assets (RONA, 12-month rolling), %	18.7%	24.2%	18.7%	24.2%	20.4%
Earnings per share, EUR	0.13	0.11	0.37	0.22	0.44

Planning a transfer to Nasdaq Helsinki Main Market

- **Board decision:** Initiated planning for a potential transfer from Nasdaq First North Growth Market Finland to Nasdaq Helsinki Main Market.
- **Target timing:** No earlier than Q2 2027.
- **Key objectives:** Increase visibility in capital markets, broaden the international and institutional investor base, and create conditions for improved share liquidity.
- **Natural next step:** Reflects DT's international profile and stage of development.
- **Business continuity:** No share issue planned; no change to the underlying business strategy.
- **IFRS transition:** Previously announced transition progressing, with comparative figures planned for December 2026 and the first IFRS financial statements review for FY2026.
- **Next steps:** Subject to necessary preparations, fulfillment of listing requirements, and Nasdaq Helsinki approval.



Sales expectation Q4 2026 and Q1 2027

Industrial
to grow double-digit
in Q4



Medical
to decline
in Q4



Security
to decline
in Q4



Q4 sales are expected to grow in APAC and the Americas, and to decline in EMEIA

YOY total net sales to **remain stable in Q4 2026** and **Q1 2027**

Business outlook

Detection Technology expects its year-on-year **total net sales to remain stable in Q4 2026 and Q1 2027.**

The geopolitical situation, new U.S. import tariffs, material constraints, and price competition create uncertainty.





FINANCIAL TARGETS

MEDIUM TERM
Annual sales growth
>10%

MEDIUM TERM
Operating margin (EBITA)
15%

ANNUAL
Dividend
30-60%



www.deetee.com